Key Points
- CEO Manner Carrie Eglinton bought 32,300 shares on March 20 at $2.93 each (about $94,639), raising her ownership by 1.5% to 2,190,874 shares valued at roughly $6.42 million.
- OraSure reported quarterly EPS of -$0.19 on Feb. 25 (missing the -$0.17 estimate) with $26.76M revenue, a negative net margin of ~59.8%, and carries an average analyst rating of "Reduce" with a $3.00 consensus target.
- Institutional investors hold about 93.5% of the stock, and several hedge funds—including Altai Capital and Millennium Management—have recently significantly increased their positions.
OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report) CEO Manner Carrie Eglinton purchased 32,300 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was purchased at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the acquisition, the chief executive officer owned 2,190,874 shares in the company, valued at approximately $6,419,260.82. This trade represents a 1.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Manner Carrie Eglinton also recently made the following trade(s):
- On Friday, March 13th, Manner Carrie Eglinton acquired 22,022 shares of OraSure Technologies stock. The shares were purchased at an average cost of $3.00 per share, with a total value of $66,066.00.
OraSure Technologies Stock Performance
OSUR opened at $3.08 on Tuesday. The company has a market cap of $212.91 million, a price-to-earnings ratio of -3.31 and a beta of 0.88. OraSure Technologies, Inc. has a one year low of $2.08 and a one year high of $4.22. The business's fifty day moving average is $2.86 and its two-hundred day moving average is $2.78.
OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). The firm had revenue of $26.76 million during the quarter, compared to analysts' expectations of $26.44 million. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%. On average, analysts predict that OraSure Technologies, Inc. will post -0.08 EPS for the current fiscal year.
Institutional Investors Weigh In On OraSure Technologies
Hedge funds have recently modified their holdings of the stock. Kotler Kevin acquired a new position in shares of OraSure Technologies in the 4th quarter valued at $4,359,000. Altai Capital Management L.P. increased its holdings in shares of OraSure Technologies by 73.4% during the 3rd quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier's stock worth $12,034,000 after buying an additional 1,586,488 shares during the last quarter. Millennium Management LLC increased its holdings in shares of OraSure Technologies by 71.1% during the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier's stock worth $6,781,000 after buying an additional 878,151 shares during the last quarter. Systematic Financial Management LP raised its position in shares of OraSure Technologies by 35.3% in the 2nd quarter. Systematic Financial Management LP now owns 2,229,076 shares of the medical instruments supplier's stock worth $6,687,000 after buying an additional 581,926 shares during the period. Finally, Archon Capital Management LLC purchased a new position in shares of OraSure Technologies in the 4th quarter worth $1,388,000. 93.50% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a "sell (d)" rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus target price of $3.00.
Get Our Latest Analysis on OSUR
OraSure Technologies Company Profile
(
Get Free Report)
OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.
The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
